[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630527":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":31,"centralContacts":36,"locations":42,"responsibleParty":57,"collaborators":26,"id":59,"slug":60,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":26,"eligibilityCriteria":65,"healthyVolunteers":61,"sex":66,"minAge":67,"maxAge":68,"enrollmentInfo":69,"targetDuration":26,"studyType":72,"phases":73,"briefSummary":75,"conditions":76,"keywords":78,"overallStatus":44,"whyStopped":26,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Ankara City Hospital Bilkent","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Lidocaine Infusion","EXPERIMENTAL","Patients in this group will receive continuous intravenous lidocaine infusion at a rate of 2 mg\u002Fkg\u002Fh throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia.",[13],"Drug: Lidocaine",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo (Normal Saline)","PLACEBO_COMPARATOR","Patients in this group will receive an intravenous infusion of normal saline at an equivalent rate throughout the surgical procedure following induction of general anesthesia. The infusion will be discontinued at the end of surgery. All patients will receive standardized general anesthesia and postoperative multimodal analgesia.",[19],"Drug: Normal Saline",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Lidocaine","Continuous intravenous lidocaine infusion will be administered during lumbar fusion surgery at a rate of 2 mg\u002Fkg\u002Fh following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.",[9],null,{"type":22,"name":28,"description":29,"armGroupLabels":30,"otherNames":26},"Normal Saline","An intravenous infusion of normal saline (0.9% sodium chloride) will be administered at an equivalent rate during surgery following induction of general anesthesia. The infusion will be maintained throughout the surgical procedure and discontinued at the end of surgery.",[15],[32],{"name":33,"affiliation":34,"role":35},"Gokhan Erdem, MD, PhD","Department of Anesthesiology and Reanimation, Ankara Bilkent City Hospital, Ankara, Turkey","PRINCIPAL_INVESTIGATOR",[37],{"name":38,"role":39,"phone":40,"phoneExt":26,"email":41},"Ankara Bilkent City Hospital","CONTACT","+90 312 552 6000","ankarasehir@saglik.gov.tr",[43],{"facility":38,"status":44,"city":45,"state":26,"zip":26,"country":46,"countryCode":26,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Ankara","Turkey (Türkiye)",{"type":48,"coordinates":49},"Point",[50,51],32.85427,39.91987,{"lat":51,"lon":50},[54],{"name":33,"role":39,"phone":55,"phoneExt":26,"email":56},"05326258766","drgokhanerdem@gmail.com",{"type":58,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100630527","intravenous-lidocaine-infusion-in-lumbar-fusion-surgery-100630527",false,"NCT07488832","Intravenous Lidocaine Infusion in Lumbar Fusion Surgery","Effect of Intraoperative Intravenous Lidocaine Infusion on Postoperative Opioid Consumption and Recovery After Lumbar Fusion Surgery: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age between 18 and 65 years\n* Scheduled for elective lumbar fusion surgery under general anesthesia\n* American Society of Anesthesiologists (ASA) physical status I-II\n* Ability to provide written informed consent\n\nExclusion Criteria:\n\n* Refusal to participate in the study\n* ASA physical status ≥III\n* Body mass index \\>35 kg\u002Fm²\n* Known allergy or hypersensitivity to lidocaine or study medications\n* Severe cardiac, hepatic, or renal disease\n* Pregnancy\n* Neurological disorders affecting pain assessment\n* Chronic opioid use\n* Use of opioids or antiemetic drugs before surgery\n* Inability to cooperate with postoperative assessments","ALL","18 Years","65 Years",{"count":70,"type":71},110,"ESTIMATED","INTERVENTIONAL",[74],"NA","Elective lumbar fusion surgery is associated with moderate to severe postoperative pain and often requires substantial perioperative opioid administration. Excessive opioid use may lead to adverse effects such as nausea, vomiting, sedation, respiratory depression, and delayed mobilization. Intravenous lidocaine infusion has been proposed as part of multimodal analgesia because of its analgesic, antihyperalgesic, and anti-inflammatory properties.\n\nThis randomized, placebo-controlled clinical trial aims to evaluate the effect of intraoperative intravenous lidocaine infusion on postoperative opioid consumption and early recovery outcomes in patients undergoing elective lumbar fusion surgery. Patients will be randomly assigned to receive either intravenous lidocaine infusion or placebo during surgery.\n\nThe primary outcome is cumulative postoperative opioid consumption within the first 24 hours after surgery. Secondary outcomes include intraoperative opioid consumption, postoperative pain scores, time to first rescue analgesic, quality of recovery, postoperative nausea and vomiting, time to mobilization, and length of hospital stay. In addition, inflammatory and oxidative stress biomarkers including interleukin-6 (IL-6) and markers of thiol-disulfide homeostasis will be measured preoperatively and postoperatively.",[77],"Lumbar Fusion Surgery",[79,80,81,82,83],"Lumbar fusion surgery","Intravenous lidocaine infusion","Postoperative pain","Opioid consumption","Postoperative recovery","2026-04-02",{"date":86,"type":87},"2026-04-08","ACTUAL",{"date":89,"type":87},"2026-04-01",{"date":91,"type":71},"2027-01-01",{"name":5,"class":6},1]